Zoetis

stockholders: Basic $ 1.65 $ 1.63 $ 3.08 $ 2.98 Diluted $ 1.65 $ 1.63 $ 3.08 $ 2.97 Weighted-average common shares outstanding: Basic 417.6 445.1 419.9 446.3 Diluted 417.7 445.5 420.1 446.7 Dividends declared per common share $ 0.530 $ 0.500 $ 1.060 $ 1.000 (a) See Note 2.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

(b) Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

(c) Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

Debt Credit Facilities In August 2025, we entered into a new revolving credit agreement with a syndicate of banks providing for a multi-year $ 1.25 billion senior unsecured revolving credit facility (the credit facility), which expires in August 2030.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

Subject to certain conditions, we have the right to increase the credit facility to up to $ 1.75 billion.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50 :1.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

2 INVESTMENTS IN GROWTH Zoetis continues to advance care for animals across the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and disruptive innovation.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Geographic expansion included approval of Solensia (frunevetmab injection) in South Korea for control of pain associated with osteoarthritis in cats.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

For the six months ended June 30, 2024, charges were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Revenue between $9.450 billion to $9.600 billion (organic operational growth of 6.5% to 8.0%) Reported net income between $2.650 billion to $2.700 billion Adjusted net income between $2.825 billion to $2.875 billion (organic operational growth of 5.5% to 7.5% ) Reported diluted EPS of $5.90 to $6.00 Adjusted diluted EPS between $6.30 to $6.40 3 This guidance reflects foreign exchange rates as of late July and the impact of enacted and assumptions on announced tariffs.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Forward-looking statements are subject to risks and uncertainties.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned Forward-Looking Statements and Factors That May Affect Future Results and Item 1A.

SEC original ↗Zoetis — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 43 Item 1A.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026

Finalizing audits with the relevant taxing authorities can include formal 12 | Table of Contents administrative and legal proceedings, and as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

SEC original ↗Zoetis — 10-Q Quarterly report10-QAug 6, 2026